相关实验视频

Updated: Jan 15, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

对MetALD和与酒精有关的肝病进行非侵入性测试

Stine Johansen^1,2, Maja Thiele^1,2, Aleksander Krag^1,2

¹Fibrosis, Fatty Liver and Steatohepatitis Research Center Odense (FLASH), Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark.

JHEP reports : innovation in hepatology

|October 16, 2025

概括

非侵入性测试 (NIT) 可以彻底改变代谢和与酒精有关的肝病 (MetALD) 和与酒精有关的肝病 (ALD) 的诊断. 这些工具可以在症状出现之前进行早期检测,改善患者的治疗结果并指导治疗.

科学领域:

肝病学肝病学是一种肝病学.
诊断医学诊断医学诊断医学
生物标志物发现发现

背景情况:

代谢和与酒精有关的肝病 (MetALD) 和与酒精有关的肝病 (ALD) 是全球肝硬化病的重要贡献者.
与代谢功能障碍相关的脂肪性肝病 (MASLD) 非常普遍,而ALD和MetALD导致不成比例的高肝脏并发症和死亡率.
有限的研究和对ALD和MetALD的临床关注被晚期诊断所加剧,通常是脱补偿后.

研究的目的:

探索非侵入性测试 (NIT) 在改变ALD和MetALD的诊断格局方面的潜力.
突出NIT在早期检测,风险评估,疾病监测和治疗反应评估中的作用.
讨论早期检测策略和MetALD和ALD中的精密医学新兴生物标志物.

主要方法:

关于肝病非侵入性检测的当前文献的综述.
分析NIT在诊断,风险分层和ALD和MetALD监测中的应用.
讨论新兴生物标志物和更广泛的实施策略.

主要成果:

NIT提供了一种实用且可扩展的方法,可以在症状出现之前,早期检测补偿性肝病.
这些测试对于风险评估,疾病监测和评估ALD和MetALD治疗疗效至关重要.
NIT已准备好成为治疗开发临床试验设计的组成部分.

结论:

非侵入性测试代表了诊断和管理ALD和MetALD的范式转变,使得早期干预成为可能.
更广泛的战略,包括政策变化,减少耻辱和改善对护理的准入,对于早期检测至关重要.
新兴的生物标志物对高风险的MetALD和ALD患者的个性化治疗方法有希望.

关键词:

生物标志物生物标志物第五个是Peth.酒精性肝病是一种肝病.没有补偿,没有补偿.预后预后预后

更多相关视频

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Published on: March 22, 2012

Author Spotlight: A Non-Invasive Tool to Assess and Differentiate Fat Patterns in Liver Using 3D Dixon MRI

Author Spotlight: A Non-Invasive Tool to Assess and Differentiate Fat Patterns in Liver Using 3D Dixon MRI

Published on: October 20, 2023

相关概念视频

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Serum Laboratory Studies, Stool Test, Breath Test

Serum Laboratory Studies, Stool Test, Breath Test

Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...